These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1261 related items for PubMed ID: 18534918

  • 1. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ, Au F, Manns BJ, McGregor SE, Hilsden RJ.
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [Abstract] [Full Text] [Related]

  • 2. Nonmedical costs of colorectal cancer screening using CT colonography.
    Heitman SJ, Au F, Manns BJ, Pattison P, Hilsden RJ.
    J Am Coll Radiol; 2010 Dec; 7(12):943-8. PubMed ID: 21129685
    [Abstract] [Full Text] [Related]

  • 3. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL, Smith A, Bampton PA, Cole SR, Young GP.
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
    Sharma VK, Corder FA, Raufman JP, Sharma P, Fennerty MB, Howden CW.
    Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
    [Abstract] [Full Text] [Related]

  • 6. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK, Corder FA, Fancher J, Howden CW.
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
    Schroy PC, Heeren TC.
    Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS.
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A cost analysis of screening methodology for family members of colorectal cancer patients.
    Rozen P, Ron E.
    Am J Gastroenterol; 1989 Dec; 84(12):1548-51. PubMed ID: 2512809
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I.
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [Abstract] [Full Text] [Related]

  • 20. [Preliminary report about the screening program for colorectal cancer by sequential fecal occult blood in Wuhan area for 4 years].
    Lu ZM, Chen JG, Zhang YX, Wang Q, Xu J, Chen C, Yang R, Xiong F, Liu C, Peng XH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):474-6. PubMed ID: 19742337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.